Hyperparathyroidism 2 with Jaw Tumors (HRPT2)

External Ids:

OMIM® 57 145001 OMIM Phenotypic Series 57 PS145000 MeSH 44 D049950 ICD10 via Orphanet 33 E21.0 UMLS via Orphanet 71 C1704981

Orphanet 58 ORPHA99880 MedGen 41 C1704981 SNOMED-CT via HPO 68 112682009 12584003 126900000 128474007 13200003 146801000119103 14760008 166702002 16932000 17173007 201637001 225595004 233870001 234689009 235494005 236423003 239832006 239838005 248274002 25064002 25081006 254919009 255037004 263681008 26544005 267026004 274667000 276645004 288939007 302849000 36348003 363481002 400006008 40739000 42399005 424568000 44598004 46720004 48638002 4996001 51398009 64859006 66931009 66999008 700423003 71938000 75694006 77867006 82525005 84229001 93163002 95315005 more UMLS 70 C1704981 C1840394

MedlinePlus Genetics : ⁴³ Hyperparathyroidism-jaw tumor syndrome is a condition characterized by overactivity of the parathyroid glands (hyperparathyroidism). The four parathyroid glands are located in the neck and secrete a hormone that regulates the body's use of calcium. Hyperparathyroidism disrupts the normal balance of calcium in the blood, which can lead to kidney stones, thinning of the bones (osteoporosis), nausea, vomiting, high blood pressure (hypertension), weakness, and fatigue.In people with hyperthyroidism-jaw tumor syndrome, hyperparathyroidism is caused by tumors that form in the parathyroid glands. Typically only one of the four parathyroid glands is affected, but in some people, tumors are found in more than one gland. The tumors are usually noncancerous (benign), in which case they are called adenomas. Approximately 15 percent of people with hyperparathyroidism-jaw tumor syndrome develop a cancerous tumor called parathyroid carcinoma. People with hyperparathyroidism-jaw tumor syndrome may also have a type of benign tumor called a fibroma in the jaw. Even though jaw tumors are specified in the name of this condition, it is estimated that only 25 to 50 percent of affected individuals have this symptom.Other tumors, both benign and cancerous, are often seen in hyperparathyroidism-jaw tumor syndrome. For example, tumors of the uterus occur in about 75 percent of women with this condition. The kidneys are affected in about 20 percent of people with hyperparathyroidism-jaw tumor syndrome. Benign kidney cysts are the most common kidney feature, but a rare tumor called Wilms tumor and other types of kidney tumor have also been found.

MalaCards based summary : Hyperparathyroidism 2 with Jaw Tumors, also known as hyperparathyroidism-jaw tumor syndrome, is related to hyperparathyroidism 1 and osteitis fibrosa. An important gene associated with Hyperparathyroidism 2 with Jaw Tumors is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways is Signaling by GPCR. The drugs Formaldehyde and Parathyroid hormone have been mentioned in the context of this disorder. Affiliated tissues include kidney, uterus and thyroid, and related phenotypes are parathyroid adenoma and primary hyperparathyroidism

GARD : ²⁰ Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is an inherited condition that causes overactivity of the parathyroid glands ( hyperparathyroidism ). These glands regulate the body's use of calcium, so overactivity can lead to high calcium levels in the blood ( hypercalcemia ). The syndrome typically begins in late adolescence or early adulthood. The hyperparathyroidism in people with HPT-JT is usually caused by a benign tumor in the parathyroid gland called a parathyroid adenoma. In some people with HPT-JT, it is caused by a cancerous (malignant) tumor called a parathyroid carcinoma. Signs and symptoms of hyperparathyroidism may include kidney stones, reduced bone mass, fatigue, muscle weakness, bone or joint pain, and constipation. Some people with HPT-JT also develop a benign tumor in the jaw called an ossifying fibroma. These tumors can grow quickly if not treated. Other features of HPT-JT may include kidney growths such as cysts, hamartomas, or rarely, Wilms tumor. Women with HPT-JT may develop benign or malignant tumors in the uterus. HPT-JT is caused by mutations in the CDC73 gene and inheritance is autosomal dominant. The diagnosis is based on the presence of signs and symptoms (identified with blood tests for hyperparathyroidism and imaging studies for tumors) and genetic testing. Treatment may involve surgery to remove a parathyroid gland with a tumor, and to remove a jaw tumor. People who are unable to have tumors removed may need a medication called cinacalcet hydrochloride to treat severe hypercalcemia.

OMIM® : ⁵⁷ Hyperparathyroidism-jaw tumor syndrome is a rare autosomal dominant disorder characterized by synchronous or metachronous occurrence of primary hyperparathyroidism, ossifying fibroma of the maxilla and/or mandible, renal tumor, and uterine tumors. It is associated with increased risk of parathyroid cancer (summary by Shibata et al., 2015). For a discussion of genetic heterogeneity of hyperparathyroidism, see HRPT1 (145000). (145001) (Updated 05-Apr-2021)

UniProtKB/Swiss-Prot : ⁷² Hyperparathyroidism 2 with jaw tumors: An autosomal dominant neoplasia syndrome characterized by primary hyperparathyroidism, ossifying fibroma of the maxilla and/or mandible, renal tumor, and uterine tumors. It is associated with increased risk of parathyroid cancer.

Clinical features from OMIM®:

145001 (Updated 05-Apr-2021)

Search NIH Clinical Center for Hyperparathyroidism 2 with Jaw Tumors

Search GEO for disease gene expression data for Hyperparathyroidism 2 with Jaw Tumors.